National Liver Cancer Screening Trial
NCT06084234
Recruiting
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), an... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/07/2025
Locations: University of Southern California, Los Angeles, California +16 locations
Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Register for Updates
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
NCT06348108
Recruiting
This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). There is currently a significant unmet need for patients with relapsed or refractory multiple myeloma (RRMM) who are triple class refractory and have been exposed to B-cell maturation antibody (BCMA) tar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: University of Calfornia, San Francisco, San Francisco, California
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Register for Updates
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06356571
Recruiting
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Berenson Cancer Center- Site Number : 8400044, West Hollywood, California +15 locations
Conditions: Plasma Cell Myeloma Refractory
Register for Updates
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
NCT06265220
Recruiting
AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies. This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Artiva Clinical Trial Site, Birmingham, Alabama +8 locations
Conditions: Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
Register for Updates
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
NCT06332807
Recruiting
This is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is an rAAV8 based vector carrying a functional copy of the human PAH gene. Participants will receive a single administration of NGGT002 and will be followed for safety and efficacy for 5 years.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/07/2025
Locations: University of Minnesota, Minneapolis, Minnesota +3 locations
Conditions: Phenylketonurias
Register for Updates
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
NCT07123038
Recruiting
To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
Gender:
ALL
Ages:
Between 18 years and 71 years
Trial Updated:
08/07/2025
Locations: UCSF Medical Center, San Francisco, California +9 locations
Conditions: Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Register for Updates
Effect of Caloric Content and Timing of Meal on Postprandial Substrate Oxidation and Pulse Wave Analysis
NCT07122765
Recruiting
The overarching aim of this research is to study the effects of caloric content and timing of meals on measures of postprandial metabolism and cardiovascular response 1. Determine the effect of caloric content on measures of postprandial metabolic flexibility and pulse wave analysis to a mixed meal challenge. 2. Determine the effect of meal timing on measures of postprandial metabolic flexibility and pulse wave analysis to a mixed meal challenge. Hypothesis: We hypothesize: 1) that hypercalori... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/07/2025
Locations: George Washington University School of Public Health, Washington, District of Columbia
Conditions: Feeding, Metabolism, Indirect Calorimetry, Blood Flow Velocity, Pulse Wave Analysis, Pulse Wave Velocity, Carbohydrate Metabolism, Fatty Acid Metabolism, Healthy Participants
Register for Updates
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
NCT06098430
Recruiting
There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal symptom burden and treatment tolerability utilizing validated patient-reported outcomes (PROs) instruments. Primary Objective: * To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pe... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
08/07/2025
Locations: University of Colorado Hospital, Aurora, Colorado +3 locations
Conditions: Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Register for Updates
An Efficacy and Safety Study of LTG-001 Following Abdominoplasty
NCT07102459
Recruiting
The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001. The main questions it aims to answer are: Does drug LTG-001 treat the acute pain after surgical abdominoplasty over 48 hours? How tolerable is LTG-001 over 48 hours? What dose of LTG-001 is better for treating post-operative / acute pain? Participants will: Take LTG-001 bid after the surgical abdomin... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/07/2025
Locations: CenExel ACMR, Atlanta, Georgia +3 locations
Conditions: Acute Pain, Postoperative Pain Control
Register for Updates
Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
NCT07125079
Recruiting
Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) is a condition where high levels of inflammation damage the lung. This is a highly morbid condition with no specific pharmacologic therapies. The investigators posit that ARDS is caused due to an exaggerated activation of immune cells and that blockade of this activation may reduce lung damage/injury and help in ARDS management and possibly recovery. To test this hypothesis, the investigators propose to generate an in vitro i... Read More
Gender:
ALL
Ages:
Between 21 years and 90 years
Trial Updated:
08/07/2025
Locations: Hospital Of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: ARDS (Acute Respiratory Distress Syndrome)
Register for Updates
Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
NCT06167291
Recruiting
To test a new radiation treatment design based on where your cancer is located. Most participants with oropharyngeal cancer are treated with radiation to both sides of the neck. However, for participants with oropharyngeal cancer on one side of the neck, receiving radiation to both sides of the neck may result in increased side effects and radiation exposure. This study is testing the safety and effectiveness of an approach that involves radiation to only one side of the neck in an effort to red... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Oropharyngeal Neoplasms, Robotic Surgery and/or Radiotherapy, Lymphoscintigraphy
Register for Updates
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
NCT06111586
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening period: at least 3 weeks and up to 5 weeks Double-blind treatment period (104 weeks): * Main treatment period: 52 weeks * Blinded extension: 52 weeks Optional Open Label Extension: 104 weeks Safety follow-up:... Read More
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
08/07/2025
Locations: University of California San Francisco - Mission Bay- Site Number : 8400012, San Francisco, California +73 locations
Conditions: Type 1 Diabetes Mellitus
Register for Updates